Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Children and Adolescents With Epilepsy With Myoclonic-Atonic Seizures
NCT05288283Phase 3Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of cannabidiol in Epilepsy with Myoclonic-Atonic Seizures (EMAS), sponsored by Jazz Pharmaceuticals plc. Started Oct 2022; status: terminated.
02
Drugs
cannabidiol
03
Conditions
Epilepsy with Myoclonic-Atonic Seizures (EMAS)
Beyond the preview
Go deeper on NCT05288283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288283.